Connor, Clark & Lunn Investment Management Ltd. Chimerix Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Chimerix Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 344,712 shares of CMRX stock, worth $303,346. This represents 0.0% of its overall portfolio holdings.

Number of Shares

344,712

Previous 206,614 66.84%

Holding current value

$303,346

Previous $181,000 76.8%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$0.77 - $1.07 $106,335 - $147,764	138,098 Added 66.84%	344,712 $320,000
Q2 2024 Aug 09, 2024	BUY	$0.87 - $1.05 $7,453 - $8,995	8,567 Added 4.33%	206,614 $181,000
Q1 2024 May 09, 2024	SELL	$0.91 - $1.26 $18,680 - $25,865	-20,528 Reduced 9.39%	198,047 $209,000
Q4 2023 Feb 09, 2024	SELL	$0.9 - $1.06 $45,096 - $53,113	-50,107 Reduced 18.65%	218,575 $209,000
Q3 2023 Nov 13, 2023	SELL	$0.94 - $1.23 $7,279 - $9,525	-7,744 Reduced 2.8%	268,682 $257,000
Q2 2023 Aug 10, 2023	BUY	$1.1 - $1.54 $60,925 - $85,295	55,387 Added 25.06%	276,426 $334,000
Q1 2023 May 09, 2023	SELL	$1.19 - $2.09 $49,224 - $86,452	-41,365 Reduced 15.76%	221,039 $278,000
Q4 2022 Feb 10, 2023	BUY	$1.67 - $2.35 $367,762 - $517,509	220,217 Added 522.0%	262,404 $488,000
Q3 2022 Nov 10, 2022	SELL	$1.81 - $2.76 $227,498 - $346,904	-125,690 Reduced 74.87%	42,187 $81,000
Q2 2022 Aug 05, 2022	SELL	$1.34 - $5.34 $79,846 - $318,194	-59,587 Reduced 26.2%	167,877 $349,000
Q1 2022 May 12, 2022	SELL	$4.58 - $6.8 $512,181 - $760,444	-111,830 Reduced 32.96%	227,464 $1.04 Million
Q4 2021 Feb 10, 2022	SELL	$5.23 - $7.18 $17,164 - $23,564	-3,282 Reduced 0.96%	339,294 $2.18 Million
Q3 2021 Nov 12, 2021	BUY	$5.94 - $8.75 $865,012 - $1.27 Million	145,625 Added 73.94%	342,576 $2.12 Million
Q2 2021 Aug 12, 2021	SELL	$7.54 - $9.79 $81,266 - $105,516	-10,778 Reduced 5.19%	196,951 $1.58 Million
Q1 2021 May 13, 2021	SELL	$4.76 - $11.25 $572,499 - $1.35 Million	-120,273 Reduced 36.67%	207,729 $2 Million
Q4 2020 Feb 16, 2021	SELL	$2.43 - $5.42 $67,867 - $151,375	-27,929 Reduced 7.85%	328,002 $1.58 Million
Q3 2020 Nov 12, 2020	SELL	$2.3 - $3.72 $150,613 - $243,600	-65,484 Reduced 15.54%	355,931 $886,000
Q2 2020 Aug 13, 2020	SELL	$1.33 - $3.63 $38,008 - $103,738	-28,578 Reduced 6.35%	421,415 $1.31 Million
Q1 2020 May 13, 2020	SELL	$1.27 - $2.33 $31,369 - $57,551	-24,700 Reduced 5.2%	449,993 $647,000
Q4 2019 Feb 12, 2020	SELL	$1.3 - $2.72 $780 - $1,632	-600 Reduced 0.13%	474,693 $964,000
Q3 2019 Nov 13, 2019	BUY	$1.93 - $4.21 $60,891 - $132,825	31,550 Added 7.11%	475,293 $1.12 Million
Q2 2019 Aug 07, 2019	BUY	$2.05 - $4.32 $143,227 - $301,825	69,867 Added 18.69%	443,743 $1.92 Million
Q1 2019 May 08, 2019	BUY	$1.79 - $3.12 $126,160 - $219,900	70,481 Added 23.23%	373,876 $785,000
Q4 2018 Feb 12, 2019	BUY	$2.24 - $3.9 $24,752 - $43,095	11,050 Added 3.78%	303,395 $780,000
Q3 2018 Nov 13, 2018	BUY	$3.58 - $4.9 $55,321 - $75,719	15,453 Added 5.58%	292,345 $1.14 Million
Q2 2018 Aug 02, 2018	BUY	$4.43 - $5.14 $5,134 - $5,957	1,159 Added 0.42%	276,892 $1.32 Million
Q1 2018 May 14, 2018	BUY	$4.65 - $5.9 $70,563 - $89,532	15,175 Added 5.82%	275,733 $1.43 Million
Q4 2017 Feb 09, 2018	SELL	$4.32 - $5.52 $29,859 - $38,154	-6,912 Reduced 2.58%	260,558 $1.21 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.25 $145,812 - $175,980	33,520 Added 14.33%	267,470 $1.4 Million
Q2 2017 Aug 14, 2017	BUY	N/A	233,950	233,950 $1.28 Million

Others Institutions Holding CMRX

# of Institutions

Shares Held

37M

Call Options Held

52.7K

Put Options Held

130K

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $77.1M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Chimerix Inc Transaction History